argenex SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

argenex SE (NASDAQ:ARGX) has been assigned an average recommendation of “Moderate Buy” from the twenty-three research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $903.7778.

A number of research analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Truist Financial lifted their price target on shares of argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. TD Cowen increased their target price on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a report on Friday, October 31st. Morgan Stanley raised their price target on shares of argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a report on Wednesday, October 1st. Finally, Jefferies Financial Group set a $818.00 target price on argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th.

Institutional Investors Weigh In On argenex

Institutional investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. Millennium Management LLC raised its stake in shares of argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after acquiring an additional 204,180 shares during the period. Adage Capital Partners GP L.L.C. raised its position in argenex by 114.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock worth $163,775,000 after purchasing an additional 158,476 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of argenex by 103.9% during the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after acquiring an additional 142,606 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Stock Down 0.4%

Shares of ARGX opened at $914.59 on Thursday. The stock has a market cap of $56.31 billion, a P/E ratio of 39.27, a P/E/G ratio of 0.94 and a beta of 0.45. The business’s fifty day moving average is $808.64 and its 200 day moving average is $678.41. argenex has a 12-month low of $510.05 and a 12-month high of $934.13.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. On average, analysts expect that argenex will post 3.13 EPS for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.